Trial · NCT01868360
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety defined by incidence and severity of adverse events at week 28 | Week 28 | The primary endpoint in the study is safety as defined by incidence and severity of adverse events in patients with corneal neovascularization undergoing corneal transplant. |
| Secondary | neovascularization regression | at time of transplant | Ability of subconjunctival aflibercept injection to regress neovascularization at time of transplant and promote graft survival after corneal transplantation |
| Secondary | Need for immunosuppression | Week 28 | Need for immunosuppression at week 28 in both treatment groups |
| Secondary | Effect on corneal infections | Through week 28 | Effect on corneal infections or other side effects through week 28 in both treatment groups |
| Secondary | Change in visual acuity | Week 28 | Change in ETDRS visual acuity from baseline at week 28 in both treatment groups |
| Secondary | Mean number of injections | Week 28 | Mean number of injections performed per patient through week 28 in patients receiving subconjunctival aflibercept injections |
| Secondary | Rescue therapy | Week 28 | Need for rescue treatment in the standard of care group through week 28 |
| Secondary | neovascularization regression | at 28 weeks after transplant | Ability of subconjunctival aflibercept injection to regress neovascularization (at 28 weeks after transplant) and promote graft survival after corneal transplantation |
| Secondary | neovascularization regression | at 52 weeks after transplantation | Ability of subconjunctival aflibercept injection to regress neovascularization at 52 weeks after transplant and promote graft survival after corneal transplantation |
| Secondary | Need for immunosuppression | week 52 | need for immunosuppression at week 52 in both treatment groups |
| Secondary | Effect on corneal infections | Through week 52 | Effect on corneal infections or other side effects through week 52 in both treatment groups. |
| Secondary | Change in visual acuity | Week 52 | Change in ETDRS visual acuity from baseline at week 52 in both treatment groups |
| Secondary | Mean number of injections | Week 52 | Mean number of injections performed per patient through week 52 in patients receiving subconjunctival aflibercept injections |
| Secondary | Rescue therapy | Week 52 | Need for rescue treatment in the standard of care group through week 52 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01868360/registered